Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Stage III Grade 1 Follicular Lymphoma
Stage III Grade 2 Follicular Lymphoma
Stage III Grade 3 Follicular Lymphoma
Stage III Small Lymphocytic Lymphoma
Stage IV Grade 1 Follicular Lymphoma
Stage IV Grade 2 Follicular Lymphoma
Stage IV Grade 3 Follicular Lymphoma
Stage IV Small Lymphocytic Lymphoma

Interventions: Drug: cyclophosphamide
Biological: rituximab
Drug: fludarabine phosphate
Drug: vincristine sulfate
Other: laboratory biomarker analysis
Drug: prednisone

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 515

Registration Number: NCT00003204

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Doxorubicin
Drug: Bleomycin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Vincristine
Radiation: Radiotherapy
Drug: Mechlorethamine
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 854

Registration Number: NCT00003389

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 529 locations

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2022-05-31

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 885

Registration Number: NCT00006455

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇩🇪
Kinderklinik, Giessen, Germany

and more 7 locations

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Biological: epoetin alfa
Drug: epirubicin hydrochloride
Biological: filgrastim
Drug: doxorubicin hydrochloride
Drug: fluorouracil
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-05

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 2104

Registration Number: NCT00014222

Locations: 🇺🇸
Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith, Arkansas, United States
🇺🇸
Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

and more 75 locations

Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-18

Lead Sponsor: Children's Hospital Los Angeles

Registration Number: NCT00006258

Locations: 🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇨🇦
Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Phase 2

Completed

Conditions: Breast Cancer
Colorectal Cancer
Kidney Cancer
Lung Cancer
Malignant Mesothelioma
Pancreatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-10

Lead Sponsor: St. Vincent Medical Center - Los Angeles

Target Recruit Count: 40

Registration Number: NCT00002475

Locations: 🇺🇸
St. Vincent Medical Center - Los Angeles, Los Angeles, California, United States

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

Phase 3

Completed

Conditions: Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 270

Registration Number: NCT00002596

Locations: 🇺🇸
FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 150 locations

Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Lymphoma Trials Office

Target Recruit Count: 310

Registration Number: NCT00005867

Locations: 🇬🇧
Horton Hospital, Banbury, England, United Kingdom
🇬🇧
Hinchingbrooke Hospital, Huntingdon, England, United Kingdom
🇬🇧
Hull Royal Infirmary, Hull, England, United Kingdom

and more 43 locations

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT00003658

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020176

Locations: 🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy